Pfizer's 2026 Challenge: Navigating the Patent Cliff and GLP-1 Race
Despite a partial recovery, Pfizer's stock remains significantly below its pandemic-era peak. As 2026 approaches, the pharmaceutical giant confronts a critical juncture defined by looming patent expirations, a high-stakes catch-up effort in the lucrative GLP-1 market, and a dividend under pressure.